AbbVie reports positive topline results from a Phase 1 multiple ascending dose study of ABBV-295, a long-acting amylin analog evaluated in adults. AbbVie (NYSE: ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1…
Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 as a Long-Term Option in Post-GLP-1 Receptor Agonist Weight Management Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for weight management and metabolic health, reinforces its position as a…
Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to…
Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced U.S. Food and Drug Administration…
MED-EL U.S. Launches Two New Rechargeable Battery Options with up to 23 Hours of Hearing for the SONNET 3 Audio Processor MED-EL U.S. announced today two new rechargeable battery options: the Standard Pro and the Micro Pro. The new options…
Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance Swiss Advanced Vision announces new clinical evidence confirming the exceptional performance of its Lucidis® intraocular lens (IOL), strengthening its position as a disruptive solution in premium cataract surgery.…
Zoetis moves to acquire the animal genomics unit of Neogen, strengthening its precision animal health capabilities. Zoetis Inc. the world’s leading animal health company, today announced it has entered into a definitive agreement with Neogen Corporation (NASDAQ: NEOG) (“Neogen”) to…
Novocure’s Leadership to Highlight Innovative Cancer Therapy at Prestigious Event Why should healthcare investors and oncology professionals be paying attention to Novocure’s upcoming participation in the Leerink Global Healthcare Conference? Novocure, a global oncology company headquartered in Baar, Switzerland, is…
New Data Supports Next-Phase Development of Targeted Alpha Therapy Why is the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) so challenging? Despite significant advances, the prognosis for men with mCRPC remains poor, with a median survival of about 31…
New Combination Therapy Demonstrates 47% Reduction in Event-Free Survival Events Why is this a game-changer for bladder cancer treatment? Merck, a global leader in healthcare, has announced groundbreaking results from the Phase 3 KEYNOTE-B15 trial, which demonstrated that the combination…
Three-Year Data Confirm Revi’s Unmatched Durability and Patient Satisfaction Why is the treatment of urgency urinary incontinence (UUI) still a significant challenge for healthcare providers? BlueWind Medical, a leader in Implantable Tibial Neuromodulation (ITNM), has introduced the Revi® System, a…
Zai Lab’s 2025 Revenue Grows 17% YoY, Paving the Way for 2026 Oncology and Immunology Milestones What does the future hold for global oncology and immunology advancements? Zai Lab Limited a biopharmaceutical company based in China and the United States,…